Stockhub

Milestone Pharmaceuticals Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

14 August 2022

13 August 2022

30 July 2022

  • curprev 08:0608:06, 30 July 2022 >Chris 666 bytes +666 Created page with "Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement w..."
Retrieved from "https://stockhub.co/research/Milestone_Pharmaceuticals_Inc."